UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
29. März 2021 08:30 ET
|
Dyadic International, Inc.
Advancing Dyadic’s proprietary owned COVID-19 vaccine candidate, DYAI-100, towards first-in-human Phase 1 clinical trial Engaged CR2O, a contract research organization, to manage and support further...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
23. März 2021 09:00 ET
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
22. März 2021 21:00 ET
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
22. März 2021 08:30 ET
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...